Neuren Pharmaceuticals has announced that its US partner Acadia Pharmaceuticals has reported third-quarter sales of its Australian-discovered and developed treatment for Rett syndrome of US$66.9 million.
Another boost for Australian company as royalties start arriving
November 6, 2023 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Government moves on general co-pay as safety gets further out of reach
July 29, 2025 - - Latest News -
'For these families, genomics is not a luxury—it’s the only viable path'
July 29, 2025 - - Latest News -
Pharmac identifies the wider societal benefit of treatments for chronic conditions
July 28, 2025 - - Latest News -
Australian cell therapy company appoints experienced executive as CEO
July 28, 2025 - - Australian Biotech -
Alterity Therapeutics reports positive topline data from Phase 2 trial of ATH434
July 28, 2025 - - Australian Biotech -
Radiopharm Theranostics receives IND approval to initiate Phase 1 study
July 28, 2025 - - Australian Biotech -
Clarity successfully completes $203 million institutional placement
July 28, 2025 - - Australian Biotech